Nicacio Leonardo Viana 4

What Happened

Nicacio Leonardo Viana, Chief Medical Officer of Protara Therapeutics (TARA), received stock awards on January 16, 2026. The Form 4 reports two grant entries: 26,000 shares (acquired at $0.00) and 158,000 derivative shares (RSUs) shown as acquired at $0.00. Total granted = 184,000 restricted stock units (no cash paid). These are awards (Form 4 transaction code "A") — compensation/retention grants rather than open-market purchases or sales.

Key Details

• Transaction date: January 16, 2026. Form 4 filed January 21, 2026 (filed one business day after the typical 2-business-day Section 16 deadline).
• Grant amounts and prices: 26,000 shares @ $0.00; 158,000 derivative RSUs @ $0.00. Total = 184,000 RSUs.
• Shares owned after transaction: Not specified in the provided excerpt — check the full Form 4 for post-transaction holdings.
• Footnotes (vesting):
  • F1: The reported shares are RSUs — each converts to one share when vested. The 26,000 RSUs vest in equal one-third installments on the 1st, 2nd and 3rd anniversaries of Jan 16, 2026, subject to continued service.
  • F2: The 158,000 RSUs vest 25% on the one-year anniversary of Jan 16, 2026, then 1/48th monthly thereafter over the next three years, subject to continued service.
• Transaction type: Award/Grant (A). The 158,000 entry is a derivative grant (contingent right to future shares).

Context

RSU grants are common executive compensation and retention tools. They do not represent an immediate cash purchase or sale and typically only convert to actual shares as they vest, subject to service conditions. For investors, awards are routine and do not by themselves indicate insider buying conviction; purchases (code P) are generally more informative about personal bullishness. If you need exact post-grant holdings or impact on outstanding shares, review the complete Form 4 filing or company disclosures.